C-path and centogene mou to enhance collaboration in lysosomal disease research and drug development

Tucson, ariz. and cambridge, mass. and rostock, germany and berlin, june 20, 2024 (globe newswire) -- critical path institute (c-path), a leader in forming collaborations that accelerate drug development, and centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a memorandum of understanding (mou) to advance drug development for lysosomal diseases (lds) and improve the quality of life for those impacted by these conditions.
CNTG Ratings Summary
CNTG Quant Ranking